Cargando…
Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort
BACKGROUND: The aim of the study was to analyze the relationship between pretreatment inflammatory biomarkers (IBs) and survival outcomes for patients with esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (neo‐CRT) and pembrolizumab. METHODS: Clinical variables an...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260499/ https://www.ncbi.nlm.nih.gov/pubmed/37089116 http://dx.doi.org/10.1111/1759-7714.14898 |
_version_ | 1785057857147764736 |
---|---|
author | Qi, Wei‐Xiang Wang, Xiaoyan Li, Chengqiang Li, Shuyan Li, Huan Xu, Feifei Chen, Jiayi Zhao, Shengguang Li, Hecheng |
author_facet | Qi, Wei‐Xiang Wang, Xiaoyan Li, Chengqiang Li, Shuyan Li, Huan Xu, Feifei Chen, Jiayi Zhao, Shengguang Li, Hecheng |
author_sort | Qi, Wei‐Xiang |
collection | PubMed |
description | BACKGROUND: The aim of the study was to analyze the relationship between pretreatment inflammatory biomarkers (IBs) and survival outcomes for patients with esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (neo‐CRT) and pembrolizumab. METHODS: Clinical variables and IBs (absolute monocyte count [AMC], absolute lymphocyte count [ALC], platelet count [PLT], neutrophil‐to‐lymphocyte ratio [NLR], platelet‐to‐lymphocyte ratio [PLR], lymphocyte‐to‐monocyte ratio [LMR], pan‐immune inflammation value [PIV], systemic immunoinflammatory index [SII], systemic immunoreactivity index [SIRI] and prognostic nutritional index [PNI]) were collected. Univariate and multivariate analysis were performed to identify the independent factors for outcomes of ESCC. RESULTS: A total of 51 patients were included. Of these, 35 patients achieved pathological complete response (pCR) after neo‐CRT and pembrolizumab (pCR: 68.6%). With a median follow‐up of 20 months, the two‐year PFS and OS of the cohort was 64% and 91%, respectively. Multivariate logistic regression analysis indicated that ALC (overall response [OR] 4.4, p = 0.051) and PLT (OR 6.7, p = 0.023) were two independent predictors for achieving pCR among ESCC treated with neo‐CRT and pembrolizumab. Multivariate Cox regression analysis showed that ALC (HR 0.27, p = 0.028) and SIRI (HR 3.13, p = 0.048) were two independent predictors associated with PFS. Kaplan Meier analysis demonstrated that the PFS of ESCC with high baseline ALC was significantly better than those with low ALC (2‐year PFS: 77% vs. 47%, p = 0.027), but not for overall survival (2‐year OS: 96% vs. 87%, p = 0.46). CONCLUSIONS: This retrospective analysis based on a prospective cohort for the first time demonstrates that pretreatment ALC is an independent predictor for achieving pCR and favorable outcomes of ESCC treated with neo‐CRT and pembrolizumab. |
format | Online Article Text |
id | pubmed-10260499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-102604992023-06-15 Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort Qi, Wei‐Xiang Wang, Xiaoyan Li, Chengqiang Li, Shuyan Li, Huan Xu, Feifei Chen, Jiayi Zhao, Shengguang Li, Hecheng Thorac Cancer Original Articles BACKGROUND: The aim of the study was to analyze the relationship between pretreatment inflammatory biomarkers (IBs) and survival outcomes for patients with esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemoradiotherapy (neo‐CRT) and pembrolizumab. METHODS: Clinical variables and IBs (absolute monocyte count [AMC], absolute lymphocyte count [ALC], platelet count [PLT], neutrophil‐to‐lymphocyte ratio [NLR], platelet‐to‐lymphocyte ratio [PLR], lymphocyte‐to‐monocyte ratio [LMR], pan‐immune inflammation value [PIV], systemic immunoinflammatory index [SII], systemic immunoreactivity index [SIRI] and prognostic nutritional index [PNI]) were collected. Univariate and multivariate analysis were performed to identify the independent factors for outcomes of ESCC. RESULTS: A total of 51 patients were included. Of these, 35 patients achieved pathological complete response (pCR) after neo‐CRT and pembrolizumab (pCR: 68.6%). With a median follow‐up of 20 months, the two‐year PFS and OS of the cohort was 64% and 91%, respectively. Multivariate logistic regression analysis indicated that ALC (overall response [OR] 4.4, p = 0.051) and PLT (OR 6.7, p = 0.023) were two independent predictors for achieving pCR among ESCC treated with neo‐CRT and pembrolizumab. Multivariate Cox regression analysis showed that ALC (HR 0.27, p = 0.028) and SIRI (HR 3.13, p = 0.048) were two independent predictors associated with PFS. Kaplan Meier analysis demonstrated that the PFS of ESCC with high baseline ALC was significantly better than those with low ALC (2‐year PFS: 77% vs. 47%, p = 0.027), but not for overall survival (2‐year OS: 96% vs. 87%, p = 0.46). CONCLUSIONS: This retrospective analysis based on a prospective cohort for the first time demonstrates that pretreatment ALC is an independent predictor for achieving pCR and favorable outcomes of ESCC treated with neo‐CRT and pembrolizumab. John Wiley & Sons Australia, Ltd 2023-04-24 /pmc/articles/PMC10260499/ /pubmed/37089116 http://dx.doi.org/10.1111/1759-7714.14898 Text en © 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Qi, Wei‐Xiang Wang, Xiaoyan Li, Chengqiang Li, Shuyan Li, Huan Xu, Feifei Chen, Jiayi Zhao, Shengguang Li, Hecheng Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort |
title | Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort |
title_full | Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort |
title_fullStr | Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort |
title_full_unstemmed | Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort |
title_short | Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort |
title_sort | pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: an analysis from a prospective cohort |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260499/ https://www.ncbi.nlm.nih.gov/pubmed/37089116 http://dx.doi.org/10.1111/1759-7714.14898 |
work_keys_str_mv | AT qiweixiang pretreatmentabsolutelymphocytecountisanindependentpredictorforsurvivaloutcomesforesophagealsquamouscellcarcinomapatientstreatedwithneoadjuvantchemoradiotherapyandpembrolizumabananalysisfromaprospectivecohort AT wangxiaoyan pretreatmentabsolutelymphocytecountisanindependentpredictorforsurvivaloutcomesforesophagealsquamouscellcarcinomapatientstreatedwithneoadjuvantchemoradiotherapyandpembrolizumabananalysisfromaprospectivecohort AT lichengqiang pretreatmentabsolutelymphocytecountisanindependentpredictorforsurvivaloutcomesforesophagealsquamouscellcarcinomapatientstreatedwithneoadjuvantchemoradiotherapyandpembrolizumabananalysisfromaprospectivecohort AT lishuyan pretreatmentabsolutelymphocytecountisanindependentpredictorforsurvivaloutcomesforesophagealsquamouscellcarcinomapatientstreatedwithneoadjuvantchemoradiotherapyandpembrolizumabananalysisfromaprospectivecohort AT lihuan pretreatmentabsolutelymphocytecountisanindependentpredictorforsurvivaloutcomesforesophagealsquamouscellcarcinomapatientstreatedwithneoadjuvantchemoradiotherapyandpembrolizumabananalysisfromaprospectivecohort AT xufeifei pretreatmentabsolutelymphocytecountisanindependentpredictorforsurvivaloutcomesforesophagealsquamouscellcarcinomapatientstreatedwithneoadjuvantchemoradiotherapyandpembrolizumabananalysisfromaprospectivecohort AT chenjiayi pretreatmentabsolutelymphocytecountisanindependentpredictorforsurvivaloutcomesforesophagealsquamouscellcarcinomapatientstreatedwithneoadjuvantchemoradiotherapyandpembrolizumabananalysisfromaprospectivecohort AT zhaoshengguang pretreatmentabsolutelymphocytecountisanindependentpredictorforsurvivaloutcomesforesophagealsquamouscellcarcinomapatientstreatedwithneoadjuvantchemoradiotherapyandpembrolizumabananalysisfromaprospectivecohort AT lihecheng pretreatmentabsolutelymphocytecountisanindependentpredictorforsurvivaloutcomesforesophagealsquamouscellcarcinomapatientstreatedwithneoadjuvantchemoradiotherapyandpembrolizumabananalysisfromaprospectivecohort |